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Abstract
Background: Physiological regulation of cellular iron involves iron export by the membrane protein, ferroportin,
the expression of which is induced by iron and negatively modulated by hepcidin. We previously showed that iron
chelation is associated with decreased HIV-1 transcription. We hypothesized that increased iron export by
ferroportin might be associated with decreased HIV-1 transcription, and degradation of ferroportin by hepcidin
might in turn induce HIV-1 transcription and replication. Here, we analyzed the effect of ferroportin and hepcidin
on HIV-1 transcription.
Results: Expression of ferroportin was associated with reduced HIV-1 transcription in 293T cells and addition of
hepcidin to ferroportin-expressing cells counteracted this effect. Furthermore, exposure of promonocytic THP-1
cells to hepcidin was associated with decreased ferroportin expression, increased intracellular iron and induction of
reporter luciferase gene expression. Finally, exposure of human primary macrophages and CD4
+ T cells to hepcidin
and iron was also associated with induction of viral production.
Conclusion: Our results suggest that the interplay between ferroportin-mediated iron export and hepcidin-
mediated degradation of ferroportin might play a role in the regulation of HIV-1 transcription and may be
important for understanding of HIV-1 pathogenesis.
Background
Movement of dietary iron from absorptive enterocytes
to portal plasma and of macrophage iron to systemic
plasma is mediated by the iron transport protein, ferro-
portin, and regulated by the hormone, hepcidin, which
is synthesized in hepatocytes [1]. Hepcidin binds to fer-
roportin, and this leads to ferroportin internalization
and degradation by lysosomes [1]. Cellular iron is
important for HIV-1 transcription, as its removal by
iron chelators is associated with inhibition of HIV-1
transcription in cultured cells [2,3].
Several studies suggest that iron stores may influence
the course of HIV infection in humans. Increased iron
stores correlated with faster HIV-1 progression in HIV-
1- positive thalassemia major patients, in HIV-positive
patients given oral iron and in HIV-positive subjects with
the haptoglobin 2-2 polymorphism [4]. Survival of HIV-
positive patients correlated inversely with higher iron
stores in bone marrow macrophages [4]. Non-anemic
HIV-positive women in Zimbabwe with increased serum
ferritin concentration had increased viral load, suggesting
that high iron stores may adversely affect HIV infection
[5]. Elevated iron predicted higher mortality in Gambian
adults infected with HIV-1 [6]. A more recent study
showed that both higher and lower iron status correlated
with increased mortality in Gambian adults [7]. Different
SLC1 (NRAMP1) polymorphisms were also shown to be
protective or associated with greater mortality [7].
Experiments by other investigators indicated that, in cul-
tured CEM T cells, excess of iron was associated with
increased HIV-1 viral replication, whereas iron chelation
with desferrioxamine (DFO) correlated with lower viral
replication [8]. Also, the iron chelators, deferoxamine and
deferiprone inhibited HIV-1 replication in human primary
peripheral blood lymphocytes and macrophages, although
the inhibition was attributed to decreased cellular prolif-
eration [9]. Recently, the topical fungicide, ciclopirox, and
the iron chelator, deferiprone, were shown to inhibit HIV-
1 gene expression at the level of transcription initiation
[10]. Both drugs interfered with the hydroxylation step in
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recent studies, the iron chelators, 311 and ICL670, inhib-
ited HIV-1 transcription by inhibiting the cellular activity
of cell cycle kinase 2 (CDK2) and by inhibiting phosphory-
lation of HIV-1 transcriptional activator protein Tat by
CDK2 [2]; we previously showed CDK2 to be important
for HIV-1 transcription [11]. Our most recent study
showed that BpT-based iron chelators, Bp4eT and Bp4aT,
prevented association of CDK9 with cyclin T1 and inhib-
ited the activity of the CDK9/cyclin T1 complex [3].
Thus, the studies of others and our own investigation
suggest that a decrease in cellular iron might have a
negative effect on host HIV-1 gene expression and be
protective against HIV-1. In this paper we investigate the
effect of the iron exporter, ferroportin, and the ferropor-
tin negative regulator, hepcidin, on HIV-1 transcription
and replication in cultured and primary cells. We
expressed ferroportin in 293T cells that have undetect-
able levels of ferroportin and analyzed the effect of ferro-
portin expression on HIV-1 transcription in the absence
and the presence of hepcidin. We proceeded to investi-
gate the effect of ferroportin on HIV-1 in cultured
T-cells and monocytes and also in human primary mono-
cytes and CD4+ T cells. Cultured and primary human
cells provide a biologically relevant system for the analy-
sis of the effect of ferroportin expression on HIV-1 tran-
scription. Our findings suggest that the interplay between
ferroportin expression and its degradation by hepcidin
may play a regulatory role in HIV-1 transcription.
Results
Expression of ferroportin inhibits HIV-1 transcription
We expressed ferroportin in 293T cells that express very
low levels of endogenous ferroportin [12]. We followed
the example of Drakesmith and colleagues [12] who
expressed CD8 as a control membrane protein that does
not transport iron, except we chose CD4, which partici-
pates in HIV-1 viral entry, but has no documented role in
HIV-1 transcription. Expression of ferroportin and CD4
was verified by immunofluorescence with anti c-myc (fer-
roportin) and anti-CD4 antibodies using FACS (Figure
1A) and Western blotting (Figure 1B). To analyze the
effect of ferroportin on HIV-1 transcription, the cells were
co-transfected with HIV-1 LTR-LacZ and CMV-GFP
reporters and Tat expression vector. Relative to control
cells that expressed CD4, Tat-induced HIV-1 transcription
was inhibited in cells that expressed ferroportin (Figure
1C). These results suggest that HIV-1 transcription is
negatively affected by the expression of ferroportin.
Ferroportin expression is associated with inhibition of
basal HIV-1 transcription
The HIV-1 promoter contains several binding sites for
host transcription factors, including three Sp1 and two
NF-B binding sites [13]. In the absence of Tat, HIV-1
basal transcription is largely regulated by the Sp1 tran-
scription factor [14,15]. Efficiency of transfection was
verified by co-expression of EGFP (Figure 1D). Basal,
non-Tat-induced activity of the WT HIV-1 LTR promo-
ter was inhibited in 293T cells that expressed ferropor-
tin (Figure 1E, panel 1). As a positive control, we used
the PP1 inhibitor, cdNIPP1 (Figure 1E, panel 1), which
we previously showed to be a potent inhibitor of Tat-
induced and basal HIV-1 transcription [16]. To deter-
mine whether the expression of ferroportin has an effect
on Sp1-driven or NF-B-driven HIV-1 transcription, we
analyzed the activity of HIV-1 promoters with inactiva-
tion of Sp1 sites or deletion of NF-B sites [17]. Expres-
sion of ferroportin was associated with inhibition of the
activity of HIV-1 LTR in both settings (Figure 1E, panels
2 and 3). These results indicate that ferroportin expres-
sion inhibits basal HIV-1 transcription driven either by
Sp1 or NF-kB.
Hepcidin mediates degradation of ferroportin and is
associated with restoration of HIV-1 transcription
Treatment of 293T cells with ferric ammonium citrate
(FAC) increased cellular ferritin level suggesting an
increase in intracellular iron. In keeping with a lack of
expression of endogenous ferroportin, exposure to hepci-
din did not alter the level of iron achieved with the incuba-
tion with FAC (Figure 2A, panel 1). Treatment of 293T
cells expressing WT ferroportin or ferroportin C326Y, a
mutant that is not sensitive to hepcidin [12], also led to an
increase in cellular ferritin. However, in keeping with the
iron-exporting function of ferroportin, the magnitude of
the increase was less than in the cells not expressing ferro-
portin (Figure 2A, panels 2 and 3). Treatment of WT fer-
roportin-expressing cells with hepcidin, followed by
treatment with FAC, was associated with a further increase
in the level of cellular ferritin (Figure 2A, panel 2). This
observation is consistent with the idea that hepcidin
reduces ferroportin expression, and is further supported
by a control experiment in which ferritin levels were not
increased in cells that expressed mutant ferroportin
C326Y, which is not sensitive to hepcidin (Figure 2A,
panel 3). Analysis of ferroportin expression by immuno-
blotting showed that hepcidin led to reduced expression of
WT, but did not reduce C326Y mutant ferroportin expres-
sion (Figure 2B). To analyze whether hepcidin leads to a
reversal of the ferroportin-associated inhibition of HIV-1
transcription, 293T cells were transfected with WT ferro-
portin, mutant ferroportin C326Y or CD4, along with the
HIV-1 LTR LacZ and Tat -expression vector, and then
treated with hepcidin. Addition of hepcidin led to reduced
inhibition of HIV-1 transcription by WT ferroportin by a
factor of 2, but did not have an effect on HIV-1 transcrip-
tion in the presence of ferroportin C326Y (Figure 2C).
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Figure 1 Expression of ferroportin inhibits HIV-1 transcription. A and B, Expression of ferroportin in 293T cells. 293T cells were transfected
with vectors expressing wild type ferroportin or CD4. At 24 hours posttransfection, the cells were stained with APC-linked antibodies against
c-myc or CD4 and analyzed by FACS (A) or the cells were lysed and expression of ferroportin and CD4 was verified by SDS-PAGE and
immunoblotting (B). In panel A, solid line - the cells stained with antibodies, shadow line - cells stained with non-specific IgG linked to APC. C,
Inhibition of Tat-induced transcription. 293T cells were transfected with vectors expressing CD4 or wild type ferroportin. At 24 hours
posttransfection, the cells were re-transfected with HIV-1 LTR-LacZ (lane 1) or and HIV-1 LTR-LacZ and HIV-1 Tat expression vectors (lane 2)
combined with EGFP expression vector. After 24 hours of culturing, the cells were lyzed and b-galactosidase activity was determined using
ONPG-based assay. D, Efficiency of transfection verified by co-expression of EGFP. 293T cells were transiently transfected with HIV-1 LTR-
Luciferase reporters in combination with CMV-EGFP. The cells were cultured for 24 hrs posttransfection, then lysed and EGFP fluorescence was
measured on Luminescence spectrometer. The results are averages of 4 independent transfections. Lane 1, WT HIV-1 LTR (-105 to +77). Lane 2,
HIV-1 LTR (-81 to+77) with NF-kB deleted sites. Lane 3, HIV-1 LTR (-105 to +77) with Sp1 inactivated sites. E, Inhibition of basal HIV-1
transcription. 293T cells were transiently transfected with indicated HIV-1 LTR-Luciferase reporters in combination with control CMV-EGFP,
ferroportin-EGFP or cdNIPP1-EGFP expression vectors. Lane 1, WT HIV-1 LTR (-105 to +77). Lane 2, HIV-1 LTR (-81 to+77) with NF-B deleted sites.
Lane 3, HIV-1 LTR (-105 to +77) with Sp1 inactivated sites. The cells were cultured for 24 hrs posttransfection, then lysed and the lysates were
used to measure GFP fluorescence and luciferase activity.
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Figure 2 Hepcidin reverses ferroportin-mediated inhibition of HIV-1 transcription. A, Ferroportin expression reduces ferritin level in 293T
cells. 293T cells were transiently transfected with c-Myc-tagged WT ferroportin-expression vector (panel 2), or mutant c-Myc-tagged C326Y
ferroportin -expression vector (panel 3). At 24 hrs posttransfection, the cells were incubated with 20 μM Ferric Ammonium Citrate for 16 hours
and then additionally treated with 100 μM cycloheximide for 1 h followed by treatment with 0.3 μM hepcidin for 4 hrs. Ferritin concentration
was analyzed by ELISA and normalized to total protein concentration that was determined by Bradford assay. B, Hepcidin reduced ferroportin
expression. Protein samples prepared as in panel A were analyzed by SDS-PAGE and Western blotting using c-Myc antibody (upper panel), or
tubulin antibodies as loading control (lower panel). C, Hepcidin restores HIV-1 transcription inhibited by ferroportin. 293T cells were transfected
with vectors expressing CD4, WT ferroportin or mutant ferroportin C326Y. At 24 hrs posttransfection, the cells were re-transfected with HIV-1 LTR-
lacZ and HIV-1 Tat expression vectors and immediately treated with indicated concentrations of hepcidin for 24 hrs. After the treatment, the cells
were lyzed and b-galactosidase activity was determined using ONPG-based assay. Results are presented relatively to the control that was not
treated with hepcidin. D, Hepcidin has no effect on transcription from CMV promoter. 293T cells were transfected with CMV-EGFP vector, treated
with hepcidin at 24 hrs posttransfection and incubated another 24 hrs. The cells were lysed and EGFP fluorescence was measured on
Luminescence spectrometer. Results are presented relatively to the control that was not treated with hepcidin.
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Page 4 of 15Also, hepcidin had no effect on HIV-1 transcription when
CD4 was expressed (Figure 2C). Hepcidin had also no
effect on the expression of EGFP (Figure 2D). Expression
of CD4, WT ferroportin or ferropotin C326Y did not have
an effect on the expression of EGFP from CMV promoter
(Figure 3A and 3B). These results suggest that the
expression of ferroportin is associated with inhibition of
HIV-1 transcription and that the inhibition can be
reversed in the presence of hepcidin.
We further examined the effect of hepcidin on ferro-
portin using a fusion of ferroportin and green fluores-
cence protein (EGFP), which allowed us to monitor and
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Figure 3 Ferroportin expression has no effect on transcription from CMV promoter. 293T cells were transiently transfected with CD4
expression vector, c-Myc-tagged WT ferroportin-expression vector or mutant c-Myc-tagged C326Y ferroportin -expression vector and also co-
transfected with CMV-EGFP expression vector. A, photographs of cells on Olympus CKX41 using blue filter for EGFP fluorescence or phase
contrast. B, EGFP fluorescence of cell lysates was measured on Luminescence spectrometer.
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Page 5 of 15quantify the level of ferroportin expression by fluores-
cence. We subcloned human WT ferropotin and ferro-
portin C326Y with an EGFP expression vector.
Expression of EGFP-fused ferroportin was analysed by
FACS which showed that WT ferroportin was sensitive
to hepcidin, but ferroportin C326Y was not (Figure 4A).
To measure a dose-dependent effect of hepcidin on the
expression of ferroportin, 293T cells were transfected
with vectors expressing WT ferroportin, mutant ferro-
portin C326Y, or an inactive mutant of a nuclear inhibi-
tor of protein phosphatase-1 (NIPP1-pA-RATA)-EGFP,
as a non-specific control which has no effect on HIV-1
transcription [16]. Addition of hepcidin resulted in a
dose-dependent decrease of WT ferroportin expression,
but no change in the expression of hepcidin-resistant
ferroportin C326Y or NIPP1-pA-RATA EGFP (Figure
4B). Co-transfection of EGFP-fused WT ferroportin or
ferroportin C326Y with HIV-1 provirus genomic clone
pNL4-3 Luc, which expresses the luciferase reporter
cloned in place of Nef [18,19], was associated with an
inhibition of luciferase expression (not shown). Treat-
ment of transfected cells with hepcidin reversed the
inhibition of HIV-1 Luc in the cells expressing WT fer-
roportin, but not in cells expressing hepcidin-resistant
ferroportin C326Y (Figure 4C). Also, hepcidin had no
effect on HIV-1 Luc expression when the cells were co-
transfected with NIPP1-pA-RATA EGFP (Figure 4C).
These results indicate that ferroportin also inhibited
HIV-1 gene expressing from the proviral genomic DNA
and that the inhibition was reversed by exposure to hep-
cidin, which leads to degradation of ferroportin. These
observations suggest that the regulation of cellular iron
by ferroportin and hepcidin might affect HIV-1 gene
expression from an HIV-1 provirus.
Ferroportin, hepcidin and HIV-1 in cultured monocytes
Next we analyzed the effect of hepcidin on HIV-1 in
macrophages, which consume aged red blood cells and
play a critical role in recycling or storing the iron
derived from the breakdown of hemoglobin. We used
cultured promonocytic THP-1 cells as a model system.
These cultured cells partially resembled human macro-
phages due to their expression of CD14 and endogenous
ferroportin [20]. As a control, we also used CEM
T-cells, a CD4+ human T-lymphoblastoid cell line that
is often used for HIV-1 infection and production stu-
dies. THP-1 cells and CEM T-cells were pre-treated
with ferric ammonium acetate (FAC), followed by ascor-
bic acid, and then infected with a VSV G-pseudotyped
HIV-1-Luc virus that expresses a luciferase reporter
(Figure 5). Treatment with hepcidin was associated with
increased luciferase activity in THP-1 cells (Figure 5A,
panel 3, unpaired t-test P < 0.0001). Analysis of ferro-
portin expression by immunoblotting in THP-1 cells
showed endogenous ferroportin expression, and treat-
ment with hepcidin was associated with decreased
expression of ferroportin (Figure 5B). In contrast, hepci-
din had no effect on HIV-1 Luc in CEM-T cells (Figure
5C, compare panels 2 and 3, unpaired t-test P = 0.93).
Analysis of ferroportin expression in CEM cells showed
that endogenous ferroportin was expressed and that
its expression was independent of the iron treatment
(Figure 5D, lanes 1 and 2); however, treatment with
hepcidin did not have an effect on the expression of fer-
roportin in CEM T-cells (Figure 5D, lane 3). These find-
ings are consistent with the possibility that hepcidin has
a moderate inducing effect on HIV-1 transcription in
cultured monocytes.
We further analyzed the effect of hepcidin on the
levels of labile iron pool (LIP) in THP-1 and CEM cells.
We followed the protocol of Cabantchik and colleagues
who saturated cells with calcein, a weak iron chelator
whose fluorescence is quenched upon binding to iron.
Treatment with a strong cell permeable iron chelator,
SIH, removes calcein-bound iron, releasing calcein; the
increase in fluorescence is measured to determine the
amount of chelatable cellular iron [21]. We used the fol-
lowing formula to plot the data: F/Fi = 1 + k(Q), where
Fi = fluorescence in the presence of quencher at time 0,
and F = fluorescence at given time, and Q- concentra-
tion of quencher. The (F-Fi)/Fi value is proportional to
the concentration of chelatable iron when equilibrium is
reached and calcein fluorescence is dequenched. Treat-
ment of THP-1 cells with iron resulted in a significant
~6-fold increase in LIP (Figure 6A). Pre-treatment of
THP-1 cells with hepcidin further increased LIP (Figure
6A). The amount of LIP was smaller in CEM T-cells,
but the addition of iron resulted also in ~2.5-fold
increase in LIP. However, hepcidin had no effect on LIP
in these cells (Figure 6B). Taken together, these results
suggest that the effect of hepcidin in increasing HIV-1
transcription in THP-1 cells was associated with reduc-
tion of ferroportin expression and accumulation of
intra-cellular iron.
Exposure to hepcidin is associated with upregulation of
HIV-1 production in primary human mononuclear cells
To investigate the role of hepcidin on HIV-1 in a phy-
siologically relevant cell model, we obtained human pri-
mary monocytes and CD4+ T cells from a commercial
source. To analyze the effect of hepcidin on HIV-1
replication in these cells, monocytes were differentiated
into macrophages, and CD4+ T cells were activated
with PHA and IL-2. Then the cells were infected with
dual-tropic HIV-1 (89.6), and reverse transcriptase activ-
ity (RT) was analysed in media. Treatment with hepci-
din was associated with an increase in RT activity in
macrophages (Figure 7A, lane 3), and treatment with
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Figure 4 Hepcidin mediates degradation of ferroportin and partially restores inhibition of HIV-1 transcription.Aa n dB ,H e p c i d i n
mediates degradation of WT but not C326Y ferroportin. 293T cells were transfected with vectors expressing WT ferroportin-EGFP, mutant C326Y
ferroportin-EGFP or non-relevant control NIPP1 pA-RATA-EGFP. Transfected cell were treated with FAC for 24 hours and then with 0.5 μM
hepcidin (A) or with indicated concentrations of hepcidin (B) for 18 hours. EGFP fluorescence was measured in intact cells using FACS (A) or in
cell lysates using Luminescence spectrometer (B). C, Ferroportin reduces inhibition of HIV-1 transcription from HIV-1 proviral DNA by WT
ferroportin-EGFP but not mutant C326Y ferroportin-EGFP. 293T cells were transfected with vectors expressing EGFP-fused wild WT ferroportin or
mutant ferroportin C326Y and also co-transfected with HIV-1 Luc genomic clone. The cells were treated with FAC for 24 hours and treated with
indicated concentrations of hepcidin. After 24 hours of treatment, the cells were lyzed and luciferase activity was determined. EGFP fluorescence
was also determined and used to normalize the results.
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Figure 5 Expression of ferroportin and effect of hepcidin in cultured THP-1 and CEM cells. THP-1 cells (A) or CEM T cells (C) were treated
with FAC for 24 hrs and then treated with 100 μM ascorbic acid for 2 hours. The cells were then infected with VSVG-pdseudotyped HIV-1 Luc
virus for 48 hrs (A and C, lanes 2 and 3). Lane 3, the cells were treated with 0.5 μM hepcidin for 6 hours. The cells were lysed, using Luclite
buffer system and the Luciferase activity was measured using Labsystems Luminoskan and the data normalization to the protein concentration.
THP-1 cells (B) or CEM T-cells (D) were treated with FAC for 24 hrs and then with 100 μM ascorbic acid for 2 hours (lane 2). The cells were then
treated with 0.5 μM hepcidin for 6 hours (lane 3). The cell lysates were resolved on 10% SDS-PAGE and immunoblotted with anti-MPT1
antibodies or with anti-tubulin antibodies. Lane 1, untreated control cells.
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Page 8 of 15hepcidin followed by iron significantly induced RT activ-
ity (Figure 7A, lane 4). In the infected CD4+ T cells,
while treatment with FAC or hepcidin alone did not
have an effect on HIV-1 RT activity (Figure 7B, lanes 1-
3), treatment of infected cells with hepcidin and FAC
together significantly induced HIV-1 RT activity (Figure
7B, lane 4). Thus, hepcidin induced HIV-1 production
in primary macrophages and T-cells suggesting that
hepcidin expression during HIV-1 infection, along
with increased cellular iron, may induce HIV-1 in both
T cells and macrophages.
Discussion
The present study suggests that expression of ferropor-
tin is associated with an inhibitory effect on HIV-1 tran-
scription and that this inhibition can be reversed by
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Figure 6 Hepcidin increases intracellular iron in THP-1 but not in CEM T-cells. THP-1 cells (A) or CEM T-cells (B) were treated as indicated
with 0.5 μM hepcidin for 3 hours and then 25 μM Ferric Sulfate for 1 hr. Then the cells were loaded with 0.1 μM calcein-AM for 10 min at 37°C,
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Page 9 of 15hepcidin. Thus the ferroportin/hepcidin interplay may
have a role in the regulation of HIV-1 in ferroportin-
expressing cells such as monocytes and macrophages as
well as, unexpectedly, in T cells.
HIV-1 infection of macrophages has been recognized
as an important component of viral pathogenesis [22].
An important function of human macrophages is a recy-
cling of iron to the bone marrow from aged red blood
cells, involving iron export by ferroportin [23]. The role
of cellular iron in the regulation of HIV-1 replication is
not well understood. We recently showed that HIV-1
transcription was inhibited by iron chelators which
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Figure 7 Hepcidin induces HIV-1 production in primary human monocytes and CD4
+ T cells. Human primary monocytes (A) and human
primary CD4+ T cells (B) were infected with dual tropic HIV-1 89.6 strain. At 24 hrs postinfection, the cells were treated with 0.3 μM hepcidin for
3 hrs and then with 100 μM FAC for 24 hrs. At 48 hours postinfection, the medium was collected, and RT was measured.
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Page 10 of 15inhibited cellular activities of the host cell co-activators
of HIV-1 transcription, CDK2 and CDK9 [2,3]. The pre-
sent study shows that increased expression of the iron
exporter, ferroportin, is associated with a significant
reduction in both basal and Tat-activated HIV transcrip-
tion. This finding extends our previous observation and
suggests that physiological regulators of cellular iron
such as ferroportin and hepcidin might be regulators of
HIV-1. It is not clear yet if ferroportin or hepcidin has
an effect on HIV-1 disease progression. Hepcidin
expression is facilitated by IL-6 and other cytokines ele-
vated during inflammation [24], and underlying inflam-
mation is a risk factor for HIV-1 disease progression
and pathogenesis [25].
HIV-1 infection of macrophages prolongs their life-time
through the induction of PI3K/Akt cell survival pathway
[26]. In non-infected macrophages, the PI3K/Akt pathway
is negatively regulated PTEN [27]. The PTEN level is low-
ered by HIV-1 Tat protein in HIV-1 infected macrophages,
inducing cell survival [26]. Interestingly, hexamethylene
bisacetamide, a potent inducer of cell differentiation and
HIV production in chronically infected cells, transiently
activates PI3K/Akt pathway; this leads to the phosphoryla-
tion of HEXIM1 and the subsequent release of active
CDK9/cyclin T1 from its transcriptionally inactive complex
with HEXIM1 and 7SK RNA in chronically infected T cell
lines and resting CD4+ T-cells [28]. Alkylphospholipds
specifically inhibit the activation of Akt kinase activity in
HIV-1 expressing macrophages and induce the death of
HIV-1 infected macrophages [29]. Because iron deficiency
downregulates Akt pathway [30], it is possible that the
increase of iron in the hepcidin-treated cells activates Akt
pathway and induces HIV-1 transcription.
Iron might be important for different proliferative
steps in the life cycle of HIV-1 including reverse-tran-
scription, activation of NF-B, regulation of HIV-1 tran-
scription, translation of viral mRNA and viral assembly
[31]. Previously, Nef, an HIV-1 accessory protein, was
shown to down regulate the expression of HFE protein,
a modulator of iron homeostasis that is mutated in the
iron-overloading disorder hereditary hemochromatosis
[32]. Deregulation of HFE by Nef increases iron levels,
which coincides with increased HIV-1 gag expression,
suggesting a beneficial effect of increased iron on the
production of HIV-1 virions and HIV-1 replication [32].
The analysis of HFE deregulation by Nef was carried
out in THP-1 cells and also in ex-vivo macrophages
expressing WT or C282Y HFE [32]. In this study, we
used VSV G-pseudotyped HIV-1, which expresses luci-
ferase in place of Nef and therefore lacks the effect of
Nef on HFE. It would be of interest to analyze replica-
tion of HIV-1 with and without Nef in primary macro-
phages, with WT and C326Y ferroportin.
Our study showed that HIV-1 transcription is induced
in the cells transfected with HIV-1 LTR LacZ expression
vector and Tat expression vector. Interestingly, higher
concentrations of hepcidin are required for the induc-
tion as compared to the induction of transcription from
HIV-1 proviral DNA. This may reflect the differences in
HIV-1 promoters; HIV-1 genomic DNA contains a full
promoter, whereas the HIV-1 LTR LacZ includes only
nucleotides -138 to +82 of the HIV-1 genomic DNA. It
is possible that induction of HIV-1 transcription by hep-
cidin involves additional transcriptional factors that act
in concert with the HIV-1 Tat protein, such as AP-1
and NFAT [33]. We showed that exposure of differen-
tiated monocytes to hepcidin induced HIV-1 produc-
tion. Recently, differentiated THP-1 cells were shown to
express ferroportin [34,35], and exposure of differen-
tiated THP-1 cells to hepcidin led to a quick degrada-
tion of ferroportin [34]. Several ferroportin mutations,
including C326Y, that were associated with greater
transferrin saturation and more prominent iron deposi-
tion in liver in vivo, were also resistant to hepcidin. This
suggests that these ferroportin mutations continuously
export iron, even in the presence of hepcidin [12,36].
Our finding that exposure of the ferroportin C326Y
mutant to hepcidin is not associated with enhanced HIV
transcription, suggests that other factors that upregulate
ferroportin might modulate HIV-1 infection as well.
Interestingly, treatment of primary CD4+ T cells with
iron and hepcidin augmented the expression of an HIV-
1 reporter gene. Thus, our results indicate that the level
of ferroportin expression might inversely relate to the
level of HIV replication, whereas hepcidin might aug-
ment HIV-1 replication. Thus, physiological iron deple-
tion by ferroportin as shown here, iron depletion by
iron chelators as we previously showed [2], or reduction
of hepcidin expression might restrict HIV-1 replication
and be thought of as potential avenues for future HIV-1
therapy. Hepcidin expression, on the other hand, may
be associated with augmentation of HIV-1 replication in
macrophages and T cells and potential acceleration of
HIV-1 progression. Future studies on the effect of hep-
cidin-resistant mutations in ferroportin and the effect of
hepcidin on HIV-1 replication in patients might provide
further insights on HIV-1 pathogenesis.
Conclusion
We are the first to address the effect of ferroportin
expression and hepcidin on HIV-1. Collectively, our
results indicate that HIV-1 transcription is lower in the
cells that express ferroportin and that inhibition of fer-
roportin expression with hepcidin is associated with
augmentation of HIV-1 transcription and viral
production.
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Materials
Mouse monoclonal anti-ferroportin (MTP-1) antibody
was purchased from Alpha Diagnostics. Anti-a-tubulin
was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). CEM and 293T cells were purchased from
ATCC (Manassas, VA). The Human Promonocytic
(THP-1) cells were obtained through the NIH AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH from Drs. Li Wu and Vineet N.
KewalRamani [37].
Cell culture
293T cells were cultured in Dulbecco’s Modified Eagles
Medium (DMEM) containing 10% fetal bovine serum
(FBS) (Life Technologies) and 1% glutamine (Life Tech-
nologies) at 37°C in the presence of 5% CO2.C E MT
cells and human primary monocyte and macrophages
(see below) were grown at 37°C in RPMI-1640 medium
(Life Technologies) supplemented with 10% fetal bovine
serum, 1% glutamine, 1% penicillin and 1% streptomy-
cin. THP-1 cells were grown under the same conditions
except that the media was supplemented with 0.05 mM
b-mercaptoethanol. The cells were seeded at 0.5 × 10
6
cells/ml into 6-well plates.
Plasmids
Human WT ferroportin and C326Y mutant ferroportin
cloned with c-Myc and histidine tags in pcDNA3.1
expression vector was kindly provided Dr. Hal Drake-
smith [12]. To generate GFP-tagged human ferroportin,
the ferroportin coding sequences from WT ferroportin
and ferroportin C326Y mutant were amplified by PCR
with primers (forward primer: GCCTCGAGATGAC-
CAGGGCGGGAGATCAC and reverse primer: GC
GGTACCGTAACAACAGATGTATTTGCTTGATTT
TC) that included XhoI and Kpn1 restriction sites
(shown in italic). The PCR products were digested with
XhoI and Kpn1 (BioLabs, Ipswich, MA) and ligated into
the pEGFP-N1 vector (Clontech, Mountain View, CA)
that was also digested with XhoI and Kpn1 and ligated.
The ligation products were transformed into E. coli
DH5a cells (Invitrogen, Carlsbad, CA) and kanamycin-
resistant colonies were selected. WT ferroportin-EGFP
and ferroportin C326Y-GFP-expressing plasmids were
purified using Qiagen (Valencia, CA) purification kit
and sequenced using Macrogen service (Rockville, MD).
The HIV-1 reporter contained HIV-1 LTR (-138 to +82)
followed by a nuclear localization signal (NLS) and the
LacZ reporter gene (courtesy of Dr. Michael Emerman,
Fred Hutchinson Cancer Institute, Seattle, WA) [38].
The pHEF-VSVG expression vector (courtesy of Dr.
Lung-Ji Chang) and pNL4-3.Luc.R
-E
- (Courtesy of Dr.
Nathaniel Landau) were obtained from the NIH AIDS
Research and Reference Reagent Program. The luciferase
reporters under the control of WT HIV-1 LTR (-105 to
+77), HIV-1 LTR (-105 to +77) with Sp1-inactivated
sites and HIV-1 LTR (-81 to +77) with NF-B-deleted
sites were courtesy of Dr. Manuel López-Cabrera (Uni-
dad de Biología Molecular, Madrid, Spain) [17]. CD4
expression vector was created by cloning CD4 coding
sequence under the control of CMV promoter in the
Adeno link vector and was a courtesy of Dr. Marina Jer-
ebtsova (Childrens National Medical Center, Washing-
ton DC).
Transfections
293T cells were seeded in 6 well plates to achieve 50%
confluence at the day of transfection. The cells were
transfected with indicated plasmids using Lipofectamine
and Plus reagents (Life Technologies) following manu-
facturer’s protocol. The efficiency of transfection was
verified using a plasmid encoding green fluorescent pro-
tein. The cells were cultured for 48 hours post-transfec-
tion and then analyzed for HIV-1 transcription or
ferroportin expression.
Western blotting
To measure the expression of c-myc tagged ferroportin
expression in 293T cell or endogenous ferroportin in
CEM and THP-1 cells, the cells were lyzed in ferritin
lysis buffer (50 mM Tris-HCl pH 7.5, 150 mm NaCl,
0.5% NP-40 and 5 mm EDTA). Equal amount of protein
(30 μg) was supplemented with SDS-loading buffer (50
mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 1% b-mer-
captoethanol, 0.1% bromophenol blue), heated at 70°C 2
min and separated on 8% polyacrylamide gel (293T
cells) or 8% Tris-Tricine gel (CEM and THP-1 cells).
Proteins were transferred to PVDF membranes (Milli-
pore, Allen, TX). Membranes were blocked with 5%
milk and incubated overnight at 4°C with anti-c-Myc
Tag (Upstate) antibodies, then washed, incubated with
anti-rabbit horseradish peroxidase linked F(ab’)2 frag-
ment (GE Healthcare UK Limited) and analyzed using
Super Signal West Pico Chemiluminescent Substrate Kit
(Pierce). For a loading control, we used mouse anti-a-
tubulin antibodies (Santa Cruz, CA).
Measurement of cellular ferritin
The cells were lysed in ferritin lysis buffer (50 mM Tris-
HCl pH 7.5, 150 mm NaCl, 0.5% NP-40 and 5 mm
EDTA) for 10 min at 4°C. Lysates were spun at 10,000 g
for 15 min to precipitate nuclear material and organelles.
Protein concentration was measured using Bradford
assay (Bio-Rad, Hercules, CA). Ferritin concentration was
measured using Spectro Ferritin ELISA kit (Ramco
Laboratories,TX). Typically, we used for the ELISA about
50 μg of total protein from 293T cell lysate or lysates of
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phages. For the iron treated monocytes or macrophages,
we used lower amounts of protein (0.5-5 μg).
Preparation of pseudotyped HIV-1 virus expressing
Luciferase (VSV G-HIV-1 Luc)
293T cells were grown on 100 mm plates and trans-
fected using Ca-Phosphate method [16] with VSVG-
expressing vector (gpHEF-VSVG) and pNL4-3.Luc.R
-E
-
molecular clone that contained two nonsense frame
shifts in Env and Vpr genes and Luciferase gene cloned
in place of nef [18,19]. At 72 h posttransfection, the
medium was collected, briefly centrifuged at 1,000 g for
10 min; and then the virus was collected by centrifuga-
tion at 4°C for 6 h at 14,000 g. The precipitated virus
was resuspended in PBS containing 10% glycerol, ali-
quoted and stored at -70°C.
Luciferase Assays, EGFP fluorescence measurements and
b-galactosidase assays
293T cells transfected with pNL4-3.Luc.R-E- plasmid or
VSVG-HIV-1 Luc infected THP-1 cells or primary
monocytes were washed with PBS, resuspended in
100 μlo fP B S / w e l li n9 6 - w e l lp l a t e .T h e n1 0 0μlo f
reconstituted Luclite buffer (Luclite kit, Perkin Elmer)
were added to each well, and after 10 min incubation
the lysates were transferred into the white plates (Perkin
Elmer) and luminescence was measured on Labsystems
Luminoscan RT (Perkin Elmer). Where indicated, the
fluorescence was measured after the measurement of
luminescence at 480 nm excitation and 510 nm emis-
sion using a Luminescence Spectrometer LS50B (Perkin-
Elmer) equipped with a robotic 96-well scanner. The
b-galactosidase assays were performed as we previously
described [16].
Measurement of labile iron
We analyzed labile iron pool (LIP) following the proto-
col of Cabantchik and colleagues who used calcein-AM
followed by iron chelators SIH to detect the amount of
chelatable cellular iron [21]. Untreated or iron treated
CEM or THP-1 cells were supplemented with 0.2 μM
calcein-AM (Molecular Probes, Invitrogen) for 10 min
at 37°C. Then the cells were washed with PBS, and
fluorescence was measured on Luminescence Spectro-
meter LS50B (Perkin-Elmer) equipped with a robotic
96-well scanner using 495 nm excitation and 515 nm
emission. This fluorescence measurement was desig-
nated as time zero. Then 30 μM SIH was added and
fluorescence was measured at the indicated time points.
W eu s e dt h ef o l l o w i n gf o r m u l at op l o tt h ed a t a :F/Fi =
1+k ( Q ) , where Fi = fluorescence in the presence of
quencher at time 0, and F = fluorescence at given time,
and Q- concentration of quencher. Thus, (F-Fi)/Fi value
is proportional to the concentration of chelatable iron
when equilibrium is reached, and calcein fluorescence is
dequenched.
Infection of human primary monocytes and CD4+ T cells
with dual tropic HIV-1
Human primary monocytes and CD4+ T cells were pur-
chased from Astarte Biologics (Redmond, WA). CD4+ T
cells were treated with PHA and IL-2 and half a million
cells were infected with dual tropic HIV-1 89.6 (AIDS
reagent Catalogue, 50 ng of p24 gag antigen). At 24 hrs
postinfection, the cells were treated with 0.3 μM hepci-
din for 3 hrs and then with 100 μMF A Cf o r2 4h r s .A t
48 hours postinfection, medium was collected, and RT
was measured. Monocytes were differentiated into
Macrophages via incubation in 10 ng/ml M-CSF for 1
week with medium change every 2 days. At day 4, they
were infected with 89.6 virus. For RT assays, viral super-
natants (10 μl) were incubated in a 96-well plate with
RT reaction mixture containing 1× RT buffer (50 mM
Tris-HCl, 1 mM DTT, 5 mM MgCl2, 20 mM KCl), 0.1%
Triton, poly(A) (10
-2 U), poly(dT) (10
-2 U) and [
3H]
TTP. The mixture was incubated overnight at 37°C and
5 μl of the reaction mix was spotted on a DEAE Filter
mat paper (PerkinElmer, Shelton, CT, USA) washed
four times with 5% Na2HPO4 and three times with
water, and then dried completely. RT activity was mea-
sured in a Betaplate counter (Wallac, Gaithersburg,
MD).
FACS analysis
C-myc linked ferroportin [12] or CD4 were expressed in
293T cells. The cells were treated with 0.4 μM calcein-
AM (Invitrogen) for 1 hr to label the cells for detection
in the blue fluorescence channel. The cells were scraped,
blocked with 5% goat serum (Sigma) and stained with
anti-c-Myc antibodies linked to Allophycocyanin (APC)
(Cayman Chemical Company) in 1:100 dilution to detect
ferroportin or anti-CD4 antibodies linked to APC (BD
Bioscience) in 1:100 dilution to detect CD4 at 4°C for 2
hrs. The cells were precipitated by centrifugation and
resuspended in the cell suspension buffer (Agilent) and
loaded to the cell checkout chip (Agilent). Fluorescence-
Activated Cell Sorting (FACS) was performed on the
cell checkout chip in 2100 Bioanalyzer (Agilent). For the
analysis of EGFP-linked ferroportin, 293T cells were
transfected with GFP-tagged human ferroportin, treated
where indicated with 0.1 μM hepcidin for 4 hrs and
GFP expression was measured by FACS (Becton-Dickin-
son) and data were analysed by FlowJo software.
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